Improving the drug selection and development process for combination devices

Drug Discovery Today

Volumn 12, Issue 19-20, 2007, Pages 844-852

  Hupcey, Maggie A Z ^a   Ekins, Sean ^b,c,d  

^a PA CONSULTING GROUP   (United States)

^b Collaborations in Chemistry ^*  (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 578; ANGIOPEPTIN; CURCUMIN; DEXAMETHASONE; ESTRADIOL; EVEROLIMUS; FLAVOPIRIDOL; GENTAMICIN; IMMUNOSUPPRESSIVE AGENT; MINOCYCLINE; PACLITAXEL; PIMECROLIMUS; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; TAMIBAROTENE; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; VINBLASTINE; ZOTAROLIMUS;

CONTROLLED RELEASE FORMULATION; DEVICE; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG EFFECT; DRUG MANUFACTURE; REVIEW;

DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; DRUG INDUSTRY; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; PHARMACEUTICAL PREPARATIONS; PROSTHESES AND IMPLANTS; RESEARCH DESIGN; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 35148837150     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.07.020     Document Type: Review

References (56)

1. Staples M., et al. Application of micro- and nano-electromechanical devices to drug delivery. Pharm. Res. 23 (2006) 847-863
2. Wu P., and Grainger D.W. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 27 (2006) 2450-2467
3. Tang Z., et al. Quantitative risk modelling for new pharmaceutical compounds. Drug Discov. Today 10 (2005) 1520-1526
4. Hunter W.L. Drug-eluting stents: beyond the hyperbole. Adv. Drug Deliv. Rev. 58 (2006) 347-349
5. Russell M.E., et al. Off-label use: an industry perspective on expanding use beyond approved indications. J. Interv. Cardiol. 19 (2006) 432-438
6. Maisel W.H. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N. Engl. J. Med. 356 (2007) 981-984
7. Curfman G.D., et al. Drug-eluting coronary stents-promise and uncertainty. N. Engl. J. Med. 356 (2007) 1059-1060
8. Farb A., and Boam A.B. Stent thrombosis redux-the FDA perspective. N. Engl. J. Med. 356 (2007) 984-987
9. Phaneuf M.D., et al. Development of an infection-resistant, bioactive wound dressing surface. J. Biomed. Mater. Res. A 74 (2005) 666-676
10. Marrey R.V., et al. Fatigue and life prediction for cobalt-chromium stents: a fracture mechanics analysis. Biomaterials 27 (2006) 1988-2000
11. Pienkowski D., et al. Multicycle mechanical performance of titanium and stainless steel transpedicular spine implants. Spine 23 (1998) 782-788
12. Gotman I. Characteristics of metals used in implants. J. Endourol. 11 (1997) 383-389
13. Tesfamariam B. Local vascular toxicokinetics of stent-based drug delivery. Toxicol. Lett. 168 (2007) 93-102
14. An Y.H., et al. Effects of sterilization on implant mechanical property and biocompatibility. Int. J. Artif. Organs 28 (2005) 1126-1137
15. Taylor R.R., et al. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur. J. Pharm. Sci. 30 (2007) 7-14
16. Levin A.D., et al. Local and systemic drug competition in drug-eluting stent tissue deposition properties. J. Controlled Release 109 (2005) 236-243
17. Yang C., and Burt H.M. Drug-eluting stents: factors governing local pharmacokinetics. Adv. Drug Deliv. Rev. 58 (2006) 402-411
18. Kaushal A.M., et al. Amorphous drug delivery systems: molecular aspects, design, and performance. Crit. Rev. Ther. Drug Carrier Syst. 21 (2004) 133-193
19. Ricciutelli M., et al. Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC. J. Pharm. Biomed. Anal. 41 (2006) 1070-1074
20. Burt H.M., and Hunter W.L. Drug-eluting stents: a multidisciplinary success story. Adv. Drug Deliv. Rev. 58 (2006) 350-357
21. Moreno R. Drug-eluting stents and other anti-restenosis devices. Rev. Esp. Cardiol. 58 (2005) 842-862
22. Lewis A., and Driver M. The benefits of drug-device combinations: an open and shut case. Eur. Biopharm. Rev. (2005) 82-87
23. Benoit M.A., et al. Antibiotic-loaded plaster of Paris implants coated with poly lactide-co-glycolide as a controlled release delivery system for the treatment of bone infections. Int. Orthop. 21 (1997) 403-408
24. Lucke M., et al. Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone 32 (2003) 521-531
25. Tanabe K., et al. Local drug delivery using coated stents: new developments and future perspectives. Curr. Pharm. Des. 10 (2004) 357-367
26. Oprea T.I., et al. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41 (2001) 1308-1315
27. Paolini G.V., et al. Global mapping of pharmacological space. Nat. Biotechnol. 24 (2006) 805-815
28. Lloyd D.G., et al. Oncology exploration: chartering cancer medicinal chemistry space. DDT 11 (2006) 149-159
29. Lewis A.L., et al. Phosphorylcholine-based polymer coatings for stent drug delivery. J. Mater. Sci. Mater. Med. 12 (2001) 865-870
30. Walter D.H., et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 110 (2004) 36-45
31. Costa M.A., and Simon D.I. Molecular basis of restenosis and drug-eluting stents. Circulation 111 (2005) 2257-2273
32. Wildemann B., et al. Local and controlled release of growth factors (combination of IGF-I and TGF-beta I, and BMP-2 alone) from a polylactide coating of titanium implants does not lead to ectopic bone formation in sheep muscle. J. Controlled Release 95 (2004) 249-256
33. Schmidmaier G., et al. Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-beta1) from a biodegradable poly(d,l-lactide) coating of osteosynthetic implants accelerates fracture healing in rats. Bone 28 (2001) 341-350
34. Palmer R.R., et al. Biological evaluation and drug delivery application of cationically modified phospholipid polymers. Biomaterials 25 (2004) 4785-4796
35. Bertrand O.F., et al. Biocompatibility aspects of new stent technology. J. Am. Coll. Cardiol. 32 (1998) 562-571
36. In: Ratner B.D., et al. (Ed). Biomaterials Science: An Introduction to Materials in Medicine (2004), Academic Press
37. (1996) Guidance for industry and FDA staff: early development considerations for innovative combination products, U.S. Department of Health and Human Services, Food and Drug Administration, Office of the Commisioner, Office of Combination Products
38. Acharya G., and Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv. Drug Deliv. Rev. 58 (2006) 387-401
39. Ashley E.A., et al. Network analysis of human in-stent restenosis. Circulation 114 (2006) 2644-2654
40. McLucas E., et al. Global gene expression analysis of the effects of vinblastine on endothelial cells, when eluted from a thermo-responsive polymer. J. Biomed. Mater. Res. A 79 (2006) 246-253
41. Nguyen K.T., et al. Molecular responses of vascular smooth muscle cells and phagocytes to curcumin-eluting bioresorbable stent materials. Biomaterials 25 (2004) 5333-5346
42. Jaschke B., et al. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. FASEB J. 18 (2004) 1285-1287
43. Mei Q., et al. Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1a/1b and cytochrome P450 3A1/2. J. Pharm. Sci. 93 (2004) 2488-2496
44. Kabanov A.V., et al. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Deliv. Rev. 55 (2003) 151-164
45. Bakhai A., et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J. Am. Coll. Cardiol. 48 (2006) 253-261
46. Anderson J.M., and Langone J.J. Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems. J. Controlled Release 57 (1999) 107-113
47. Kaiser C., et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
48. Liptak P., and Ivanyi B. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat. Clin. Pract. Nephrol. 2 (2006) 398-404 (quiz following 404)
49. Lin C.M., et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. 34 (1988) 200-208
50. Picard N., et al. Metabolism of sirolimus in the presence or absence of cyclosporin by genotyped human liver microsomes and recombinant cytochromes P450 3a4 and 3a5. Drug Metab. Dispos. (2006)
51. Dai D., et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11 (2001) 597-607
52. Walsky R.L., et al. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J. Clin. Pharmacol. 45 (2005) 68-78
53. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov. Today 9 (2004) 276-285
54. Minamiyama Y., et al. Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 452 (1999) 165-169
55. Michaelis U.R., et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J. Cell Sci. 118 Pt 23 (2005) 5489-5498
56. Gomella L., and Haist S. Clinician's Pocket Drug Reference 2004 (2004), McGraw-Hill